GE, the Global Good Fund and Access Bio will make and distribute rapid diagnostic technologies for asymptomatic malaria detection in low-resource countries under a licensing deal. The agreement also covers a technology that supports the creation of malarial serology tests for Plasmodium antibodies, as well as Plasmodium lactate dehydrogenase rapid diagnostic tests for malarial parasite detection and a highly sensitive diagnostic test for identification of malaria-related proteins.
GE enters licensing deal on asymptomatic malaria detection
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.